Paclitaxel with bevacizumab (PB) as first-line therapy for metastatic breast cancer: Our experience.

e11013 Background: In a clinical trial of 722 patients (pts) with locally recurrent metastatic breast cancer (MBC) solvent-based paclitaxel 90 mg/m2 was administered intravenously (IV) over 1 hr weekly for 3 weeks (wPac) followed by a week of rest (q3/4w) alone or in combination with bevacizumab (Bev) 10 mg/kg every 2 weeks (q2w) (E2100 Trial). As compared with single agent, the combination had a greater median progression-free survival (PFS; 11.4 months (mo) vs. 6.11 mo, p < 0.0001) and overall response rate (ORR; 30% vs. 14%, p < 0.0001). Methods: We reviewed data for 16 patients: pts ≥20 years with HER2-negative measurable MBC, ECOG PS≤1 and no prior chemotherapy for MBC received Bev 10 mg/kg d 1 and 15 with wPac 90 mg/m2, d 1, 8, and 15 q4w, as in E2100 trial. Coprimary endpoints were time to progression (TTP) and safety. Secondary endpoints included ORR (RECIST v1) and overall survival (OS). Results: A total of 16 patients were registered and evaluated between June 2009 and September 2010. Median age...